From Population to Patient: Can Cycle 1 177 Lu-PSMA-617 Dosimetry Guide Individual Therapy? Results from Pan-Canadian PR21 trial (NCT04663997) (EANM 2026) - Sep 29, 2026 - Abstract #OP-685; Pres time: Oct 20, 2026; 03:00 PM - 04:30 PM; Location: Hall B; P2 | "Cycle 1 dosimetry provides reasonable population-level estimates of cumulative organ absorbed dose, particularly for kidneys and red marrow, but shows substantial individual-level variability. These findings suggest cycle 1 dosimetry alone is insufficient for accurate patient-specific treatment adaptation. When individualized absorbed dose guidance is intended, additional longitudinal dosimetry is required."
Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
S. Kurkowska 1; P. L. Esquinas 2; X. Hou 2; N. Colpo 1; C. Williams 1; C. Dellar 3; W. Parulekar 3; F. Saad 4; K. Zukotynski 5; K. Chi 2; J. M. Beauregard 6, 7; F. Benard 1; C. Uribe 1
|